Protea Biosciences Group, Inc. 4
4 · Protea Biosciences Group, Inc. · Filed Apr 4, 2017
Insider Transaction Report
Form 4
ROBERSON ED
Director
Transactions
- Other
Common Stock
2017-03-24+400,000→ 1,005,456 total - Other
Class A Warrant (right to buy)
2017-03-24+400,000→ 1,123,927 totalExercise: $0.09From: 2017-03-24Exp: 2018-09-24→ Common Stock (400,000 underlying) - Other
Class B Warrant (right to buy)
2017-03-24+400,000→ 1,123,927 totalExercise: $0.11From: 2017-03-24Exp: 2022-03-24→ Common Stock (400,000 underlying)
Footnotes (4)
- [F1]Mr. Roberson held $30,000 of outstanding principal indebtedness and accrued unpaid interest of the Issuer ("Unsecured Debt"). On March 24, 2017, Mr. Roberson exchanged $30,000 of Unsecured Debt of the Issuer, for units of the Issuer's equity securities, consisting of (a) an aggregate of 400,000 shares of common stock, $0.0001 par value per share, of the Issuer ("Common Stock"), valued at $0.075 per share, (b) 18 month Class A warrants to purchase 400,000 shares of Common Stock at an exercise price of $0.09 per share ("Class A Warrant"), and (c) five year Class B warrants to purchase another 400,000 shares at an exercise price of $0.1125 per share ("Class B Warrant").
- [F2]The shares of Common Stock reported in Column 5 and 7 are the number of shares of Common Stock issuable upon exercise of the Class A Warrant and/or Class B Warrant.
- [F3]Includes 67,856 shares of Common Stock owned of record by Raymond James & Associates, Inc., an IRA account of Ed Roberson.
- [F4]Includes 857,260 shares of Common Stock to be acquired upon the exercise of warrants and 266,667 shares of Common Stock to be acquired upon the exercise of stock options.